Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.62 |
| ▸ | CYP3A5 | P20815 | 8/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566635 | 0.80 | CYP3A4 (0.70) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL6904433 | 0.78 | CYP3A4 (1.00) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL10431413 | 0.77 | CYP3A4 (0.92) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL9455477 | 0.76 | MAPT (0.45) | CYP19A1SMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL7685830 | 0.75 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL5566622 | 0.75 | KMT2A (0.44) | CYP3A4SMN1; SMN2MEN1MAPTKMT2A | |
| Fenarimol SCHEMBL8408558 | 0.73 | CYP3A4 (0.90) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL11858453 | 0.72 | HSD17B10 (0.51) | CYP3A4SMN1; SMN2MEN1MAPTKMT2A | |
| Triarimol SCHEMBL10335859 | 0.72 | CYP19A1 (0.65) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL27368720 | 0.70 | CYP3A4 (0.86) | CYP19A1CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000040-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2005-04-28 | — | — | US | disclosed |
| US-6867207-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-15 | — | — | US | disclosed |
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2004-08-26 | — | — | US | disclosed |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | LACRAMPE JEAN FERNAND ARMAND (FR) | 2002-06-13 | — | — | US | disclosed |
| EP-1000040-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002505-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | IL6ST, CXCR5, ALOX5 | CYP19A1 2652/4885CYP3A4 767/4885CYP3A5 235/4885 |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | CXCR5, HCAR3, IL6ST | CYP19A1 2336/4885CYP3A4 831/4885CYP3A5 139/4885 |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | IL6ST, ALOX5, IL5 | CYP19A1 2489/4885CYP3A4 586/4885CYP3A5 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.